Pfizer and Biohaven have entered into a commercialization arrangement and Pfizer will be leading on the reimbursement and commercialization activities for this technology in the UK. The scope for the appraisal has been updated accordingly and is available in the documents section of this topic page. The scope has also been amended to reflect the publication of updated NICE guidance on fremanezumab (TA764) following a rapid review. TA764 has replaced TA631.